Mesalamine (5-aminosalicylic acid (5-ASA)) is an anti-inflammatory drug indicated for the treatment of ulcerative colitis (UC) and Crohn’s disease (CD).
From In Vitro Dissolution Testing to In Vivo Clinical Pharmacokinetic Prediction Using PBPK Models for Oral Cavity Drug Products
This work develops a novel in vitro to in vivo extrapolation (IVIVE) method for the prediction of in vivo pharmacokinetic (PK) for oral cavity drug products (DP).
PBPK-Based Prediction of Obesity-Mediated Changes in Small Molecule Pharmacokinetics
Obesity is associated with fat accumulation, combined with physiological alterations, (changes in organ sizes, blood flows, and metabolic enzyme activities).
Predicting Aflibercept Local Exposure in Humans Using an Ocular PBPK Model
Developing both innovative and generic ophthalmic drug products remains a significant hurdle for the pharmaceutical industry.
From Bench to Computational Modeling: Integrating Mitochondrial Stress Data from a Rat Hepatic Ischemia-Reperfusion Injury Model into a Preclinical and Human Quantitative Systems Toxicology Platform
Hepatic ischemia-reperfusion injury (IRI) contributes significantly to liver dysfunction post-surgery and transplantation
Enhancing Drug Formulation Development Through PBBM and GastroPlus®
As anyone who has worked in the pharmaceutical industry knows, there is a constant push to accelerate and optimize development processes.
GastroPlus® X.2: The Deep Dive Webinar Series – Introducing Orchestrator, Automation for Complex PBPK/PBBM Modeling in GPX.2
What if you could design a complex workflow, then set it into motion with a single click?
Exploring Artificial Intelligence’s Potential to Enhance Conventional Anticancer Drug Development
Cancer affects one in three to four people globally, with over 20 million new cases and 10 million deaths annually, projected to rise to 35 million cases by 2050. Developing effective cancer treatments is crucial, but the drug discovery process is a highly complex and expensive endeavor, with success rates sitting well below 10% for oncologic therapies
Mechanistic Pharmacokinetic Models for Inhaled Drug Development: Pulmonary Physiological and Structural Characteristics and Modeling Approaches
Pulmonary drug delivery via inhalation offers significant clinical benefits including rapid onset of action and targeted drug administration, which minimizes systemic adverse effects.
Simulated Pharmacokinetic Compatibility of Tamoxifen and Estradiol: Insights from a PBPK Model in Hormone-Responsive Breast Cancer
Although traditionally contraindicated, the coadministration of tamoxifen and estradiol may hold clinical relevance in specific contexts, particularly in breast cancer survivors with premature menopause...
Get Under the Skin with GPX.2
If you’re working on the development of injectable therapies, then this webinar is for you
Introducing Orchestrator – Faster Workflows, Smarter Science
As scientists working in pre-clinical drug development, we are constantly balancing the need for rigorous, mechanistic modeling with the realities of fast-moving project timelines.
Whole-Body Disposition and Metabolism of [14C]-2,4,4′-Trichlorobiphenyl (PCB28) Following Lung Administration in Rats
Toxicities of lower-chlorinated biphenyls (LC-PCBs) have drawn increasing attention due to growing evidence of their presence in school indoor air, with 2,4,4′-trichlorobiphenyl (PCB28) being a prevalent congener.
Novel Workflow for Non-Animal PBK Modelling of UV Filters: Oxybenzone as a Case Study
Physiologically based kinetics (PBK) modelling provides (internal) exposure concentrations. We used a PBK model parameterized exclusively with in silico and in vitro data in a bottom-up approach to predict the pharmacokinetics of oxybenzone, a UV filter, present in two formulations (for which dose-normalized Cmax and AUC from clinical studies were different).
Simulations Plus Announces Preliminary Fiscal Year 2025 Results and Fiscal Year 2026 Guidance
Provides preliminary fiscal 2026 revenue guidance of $79 to $82 million and adjusted diluted EPS guidance of $1.03 to $1.10
Fourth quarter and fiscal year 2025 results to be reported December 1, 2025
Emerging Perspectives on Leveraging Physiologically Based Biopharmaceutics Modeling (PBBM) for BCS Class III Biowaivers: a Webinar Summary
The regulatory framework for Biopharmaceutics Classification System (BCS) class III drug products provides a pathway for streamlined biowaivers in drug development, eliminating the need for expensive...
QSAR-based Physiologically Based Pharmacokinetic (PBPK) Modeling for 34 Fentanyl Analogs: Model Validation, Human Pharmacokinetic Prediction and Abuse Risk Insights
Fentanyl analogs, as emerging new psychoactive substances (NPS), pose a global public health threat due to widespread abuse, high toxicity, and frequent overdose fatalities.
AI-Driven Knowledge Management in PBPK Modeling: Challenges & Opportunities
High-quality data is the foundation of every major AI advance
Advancing Kidney Safety: What’s New in RENAsym® 2A
Drug-induced kidney injury remains a significant concern in pharmaceutical development, with traditional methods often falling short in predicting renal toxicity across diverse compounds and patient populations.
Development of Co-Amorphous Systems for Inhalation Therapy—Part 2: In Silico Guided Co-Amorphous Rifampicin–Moxifloxacin and –Ethambutol Formulations
Tuberculosis (TB) remains a global health challenge due to long treatment durations, poor adherence, and growing drug resistance. Inhalable co-amorphous systems (COAMS) offer a promising strategy for targeted pulmonary delivery...